Alendronate Inhibits VEGF Expression in Growth Plate Chondrocytes by Acting on the Mevalonate Pathway

K.D. Evans and A.M. Oberbauer*

Department of Animal Science, University of California, One Shields Ave., Davis, CA 95616, USA

Abstract: Bisphosphonates decrease chondrocyte turnover at the growth plate and impact bone growth. Likewise vascular endothelial growth factor (VEGF) plays an important role in endochondral bone elongation by influencing chondrocyte turnover at the growth plate. To investigate whether the action of bisphosphonate on the growth plate works through VEGF, VEGF protein expression and isoform transcription in endochondral chondrocytes isolated from growing mice and treated with a clinically used bisphosphonate, alendronate, were assessed. Alendronate at 10μM and 100μM concentrations decreased secreted VEGF protein expression but not cell associated protein. Bisphosphonates are known to inhibit the mevalonate intracellular signaling pathway used by VEGF. Addition of the mevalonate pathway intermediates farnesol (FOH) and geranylgeraniol (GGOH) interacted with the low concentration of alendronate to further decrease secreted VEGF protein whereas FOH partially restored VEGF protein secretion when combined with the high alendronate. Similar to the protein data, the addition of alendronate decreased VEGF mRNA isoforms. VEGF mRNA levels were rescued by the GGOH mevalonate pathway intermediate at the low alendronate dose whereas neither intermediate consistently restored the VEGF mRNA levels at the high alendronate dose. Thus, the bisphosphonate alendronate impairs growth plate chondrocyte turnover by down-regulating the secreted forms of VEGF mRNA and protein by inhibiting the mevalonate pathway.

Keywords: VEGF, chondrocyte, bisphosphonate.

INTRODUCTION

Bisphosphonate drugs inhibit osteoclastic resorption and therefore are used to treat bone disease characterized by increased osteoclast action [1, 2]. Bisphosphonates are used also to regulate circulating vascular endothelial growth factor (VEGF) concentrations within the body as a prophylactic against cancer metastasis [3].

A major function of VEGF is to modulate endochondral chondrocyte turnover during bone growth and development [4]. VEGF is synthesized from several isoforms each exerting differential effects on endochondral ossification [5]. The mature murine VEGF protein is translated from three primary transcripts, VEGF 120, VEGF 164, and VEGF 188 [6], generated by post-transcriptional exon splicing giving rise to protein isoforms that differ in extra cellular matrix binding affinities. The protein product of VEGF 120 is soluble with low binding affinity for extracellular matrix. In contrast, the VEGF 164 protein product is partially soluble but also binds to extracellular matrix while VEGF 188 is not soluble and binds only to matrix proteoglycans.

Because angiogenesis is a key element to osteogenesis, impairment of vascular invasion alters bone elongation. Reduced vascular invasion at the chondro-osseous junction has been observed with bisphosphonate treatment [7] corroborating the generalized decrease of VEGF and vascular expansion observed in bisphosphonate treated cancer patients. Nitrogen containing bisphosphonates such as alendronate inhibit the mevalonate pathway that produces isoprenoid lipids essential for the cell membrane anchoring of small GTP associated proteins (e.g., Ras, Rac, Rho) used in intracellular molecular signaling pathways [8]. Bisphosphonate treatment spanning the growth phase of juvenile patients may impact the events controlling longitudinal bone growth doing so by altering VEGF expression as a consequence of disrupting the mevalonate pathway.

In this study, the effect of a nitrogen containing bisphosphonate, alendronate, on VEGF transcript isoform expression and VEGF protein production in endochondral chondrocytes was assessed. Further, by providing mevalonate pathway intermediates, the question of how alendronate exerted its action on VEGF could be investigated. Characterizing the response of VEGF to bisphosphonates may provide insight on the impact of therapeutic bisphosphonate treatment on cartilage to bone conversion.

METHODS

Cell Culture

All experimental protocols used in this research were reviewed and approved by the institutional animal care and use committee of the University of California, Davis. Primary chondrocytes were isolated from costochondral growth plates of 15 stock inbred C57BL/6J male mice aged 28 days (Jackson Laboratories, Bar Harbor, ME, USA) as previously detailed [9, 10]. The chondrocyte preparation was, based on cellular phenotype and previous confirmation with density gradients [10], 50% hypertrophic, 40% proliferative, and 10% resting cell composition with trypan blue exclusion exceeding 95%. Chondrocytes were plated in
DMEM/F12 + 10% FBS in 24 well microplates (Corning COSTAR, Corning, NY, USA) at a density of approximately 100,000 cells per ml (2 ml per well) and allowed to recover for 48 h.

After the initial 48h, media for the primary chondrocytes were replaced with DMEM/F12 + ITS media (BD biosciences, Bedford, MA, USA) containing 1% FBS. ITS media supplements low serum media and maintains endochondral chondrocyte growth in culture [11]. A key regulator of endochondral bone maturation is insulin like growth factor-I (IGF-I) [12] known to preferentially activate growth plate growth factor-I (IGF-I) [12] and endochondral bone maturation [11]. IGF-I also regulates VEGF expression [13]. Thus all media were supplemented with 100ng/ml IGF-I (Peprotech Inc., Rocky Hill, NJ, USA) to ensure activation of the mevalonate pathway and expression of VEGF.

Triplicate chondrocyte cultures were incubated with 10μM or 100μM of alendronate either alone or in the presence of mevalonate pathway intermediates, 10μM farnesol (FOH) or 10μM geranylgeraniol (GGOH). The alendronate concentrations were selected based on concentrations experienced by patients and those used in culture experiments: estimated cellular concentrations experienced by patients receiving bisphosphonates for osteoporosis are 10μM or less [14] while cultured canine fibroblasts and osteosarcoma cells at a wide range of concentrations (1000 to 0.001μM) did not impair growth or viability [15]. FOH (Alfa Aesar, Ward Hill, MA, USA) and GGOH (ICN pharmaceuticals, Aurora, OH) are metabolized to farnesylpyrophosphate and geranylgeranylpseudophosphate, essential for the posttranslational modifications necessary for membrane localization and activation of small G-proteins. The 10μM concentration of mevalonate intermediates was based on published literature demonstrating that this level had no independent effect on bone [16]. Cells were incubated with the compounds for 24 h prior to collection for VEGF mRNA analysis. The entire experiment of 15 animals was fully replicated for treatment groups of six independent cultures.

mRNA Analysis

Total RNA was extracted and reverse transcribed for real-time PCR of the target VEGF-A gene transcripts (VEGF120, VEGF164, VEGF188) using a Taqman assay as previously described [10]. The Taqman systems were designed to be splice-variant specific by placing the reverse primer over the alternatively spliced exon [10]. The amplified PCR products were designed to be approximately 150 base pairs in length. Primer sequences were identified by analyzing sequences in GenBank using Vector NTI 9.1 and NCBI BLAST software. A universal forward primer was used 5′-GGAGAGATGAGCTTCCTACAGCA-3′ for all isoforms. The reverse primer was isoform specific: 5′-CTCGGGTGTCACTTTTTTCT-3′ (VEGF 120); 5′-GCTCACAGTATTTTCTGCTT-3′ (VEGF 164); 5′-TCTCCTAAGCTTATTTTTTCTGG-3′ (VEGF 188). The Taqman probe was 5′-GATGTGAAAGGAGACCCAAGAAACGGAGACAAG3′. The amplicons for each isoform were validated by agarose gel electrophoresis. To identify the most appropriate endogenous control, five commonly used housekeeping genes were assessed: a TaqMan PCR system recognizing 18S rRNA (ssrRNA), GAPDH (glyceraldehyde 3-phosphate dehydrogenase), HPRT1 (hypoxanthine phosphoribosyltransferase 1), B2M (beta 2 microglobulin), and TFR2 (transferrin receptor 2; CD71). The murine HPRT1 was selected and used as the endogenous control because it was the most stably expressed gene for these chondrocytes. Final quantitation was done by the comparative CT method (User Bulletin no. 2, Applied Biosystems) and is reported as relative transcript level relative to a calibrator cDNA.

Briefly, the signal of the endogenous HPRT1 control was used to normalize the target gene signals of each sample. The difference in the CT for the target and the CT for the internal control, termed ΔCT, was calibrated against the control value for cells treated only with ITS plus IGF-I. The relative linear amount of target molecules relative to the calibrator, was calculated by 2^-ΔΔCT; thus, target gene transcript levels are expressed as an n-fold difference relative to the calibrator level from cells treated with ITS plus IGF-I.

Protein Analysis

Additional triplicate culture wells were treated and the media and cell lysates from each treatment group were collected 72 h after treatment administration for VEGF protein determination. Cells in each well were lysed in 0.1% triton-x100 in PBS with the lysates stored at -20 °C; prior to assay, lysates were centrifuged and the supernatants collected. Total protein content was assayed in media and cell lysates using the Bradford colorimetric method. Secreted VEGF protein in media and that associated with the cells were quantified by the commercially available enzyme-linked immunosorbent assay according to the manufacturer’s directions (Quantikine murine VEGF, R & D Systems, Minneapolis, MN, USA) and adjusted for total protein. Again, the entire experiment was fully replicated.

Statistics

VEGF protein expression and transcript isoform levels across treatments were analyzed by least-squares analysis of variance procedures using PROC GLM of SAS (version 8.0, 2001). Post hoc analyses were done using a Bonferroni adjustment. All experiments were replicated fully with the experimental replications yielding similar patterns of VEGF transcript and protein expression.

RESULTS

VEGF Isoforms

Growth plate chondrocytes treated with the low dose of alendronate (10μM) exhibited a 37% decrease in VEGF 120 and VEGF 164 isoform levels whereas the VEGF 188 isoform level was unchanged (Fig. 1; p < 0.01). The high alendronate dose (100 μM) similarly reduced VEGF 120 and VEGF 164 isoform levels by 32-36% but also reduced the VEGF 188 isoform level to the same extent (Fig. 1; p < 0.01).

Both VEGF 120 and VEGF 164 transcript levels underwent a partial to complete rescue with the addition of GGOH in combination with the low alendronate dose, whereas the addition of FOH only partially restored the VEGF 120 isoform level, but not the 164 transcript. Co-treatment of the cells with both FOH and GGOH in the
Alendronate Inhibits VEGF in the Growth Plate

The Open Orthopaedics Journal, 2009, Volume 3

85

presence of the low alendronate dose yielded the same results as cells treated with GGOH alone (data not shown). At the high dose of alendronate, the mevalonate intermediates were minimally effective at restoring the VEGF transcript levels with only the levels of VEGF 188 partially restored. In contrast to the results seen for the low alendronate dose, only the addition of FOH modestly restored VEGF 188 levels; neither FOH nor GGOH restored the 120 or 164 isoform levels. Provision of FOH and GGOH in combination with the high dose of alendronate was not different than either compound alone (data not shown).

**VEGF Protein**

Total VEGF secreted protein, adjusted for total protein, was decreased 32% and 50% by treatment with 10µM or 100µM alendronate, respectively (p < 0.001) (Table 1). The decrease in VEGF secreted protein induced by the alendronate at the low concentration was not restored to control levels by the addition of FOH and GGOH. Rather, addition of FOH to the 10µM dose of alendronate significantly decreased VEGF secreted protein beyond that observed for alendronate alone, reaching levels comparable to that caused by 100µM alendronate. The decrease in VEGF secreted protein observed in the 100µM dose was nearly restored by FOH but not by GGOH. This corresponded to the rescue seen for the VEGF isoform levels with the addition of FOH at the higher alendronate dose.

Cell associated VEGF was increased by the 10 µM low alendronate dose and the addition of the mevalonate pathway intermediates did not further augment those levels. In contrast, the 100µM high alendronate dose did not alter cell associated protein but addition of either FOH or GGOH reduced VEGF levels, similar to the secreted VEGF response for the low alendronate dose.

**DISCUSSION**

Nitrogen containing bisphosphonate drugs are the primary non-surgical treatment for decreasing osteoclast action in various bone diseases such as Paget’s disease, osteoporosis and osteogenesis imperfecta. Bisphosphonates appear to improve tendon repair and prosthetic bone surgeries [17, 18] possibly by reducing apoptosis of osteoblasts and osteocytes [19]. Further, bisphosphonates have been suggested as a preventative for osteoarthritis [20]. Bisphosphonate drugs are also used extensively to reduce circulating VEGF thereby reducing metastasis for many forms of cancer and ameliorate bone pain associated with bone cancers [3, 19, 21-24]. Because VEGF is important in growth plate chondrocyte turnover and survival [4, 25], inhibition of VEGF by prolonged bisphosphonate treatment for bone disease or cancer may perturb growth plate chondrocyte turnover in juvenile patients.

In the present study, alendronate reduced VEGF transcript isoform levels and protein expression in endochondral chondrocytes by ~ 40%. Such a degree of inhibition is likely to have significant biological effects as similar reductions achieved by siRNA evoke physiological consequences [for example, reference 26]. The VEGF 120 isoform is the main secreted protein form of VEGF with VEGF 164 encoding both a secreted and a membrane bound protein and VEGF 188 strictly being membrane bound [27]. In the growth plate of juvenile mice the most abundant VEGF isoform is the VEGF 120 transcript representing 76.3% of all VEGF mRNA transcripts, whereas VEGF 164 and 188 represent 15.3% and 8.4%, respectively [10]. Treatment of chondrocytes with the low alendronate dose, the dose most similar to clinical studies, preferentially decreased the two predominant isoforms responsible for secreted protein: VEGF 120 and VEGF 164 without altering
preferential decrease in the secreted VEGF forms by regulation of VEGF isoform expression has been reported. Isoforms have distinct roles in angiogenesis and differential VEGF188 mRNA used for the bound form. The individual concentrations, geranylgeranylated proteins such as Rho are known to be regulated by Ras, a farnesylated G protein [37]. Though recent studies suggest that geranylgeranylated Rho may also be involved in regulating VEGF expression [38]. The differential response to the mevalonate pathway within growth plate chondrocytes. Alendronate, a nitrogen containing bisphosphonate, reduced secreted VEGF at the mRNA, protein, and secretory levels in growth plate chondrocytes indicating that.

Table 1. VEGF Protein (pg/ml), Adjusted for Total Protein, Secreted into the Media or Cell Associated from Murine Endochondral Chondrocytes Treated with Alendronate (ALN) and Mevalonate Intermediates Farnesol (FOH) and Geranylgeraniol (GGOH) for 72 h

| Media VEGF Protein | Control | ALN | ALN + FOH | ALN + GGOH |
|--------------------|---------|-----|-----------|------------|
| 10μM ALN           | 306.9 ± 4.6<sup>a</sup> | 207.2 ± 4.6<sup>b</sup> | 132.0 ± 4.6<sup>c</sup> | 196.3 ± 4.6<sup>d</sup> |
| 100μM ALN          | 279.5 ± 4.6<sup>e</sup> | 137.8 ± 4.6<sup>f</sup> | 239.4 ± 4.6<sup>g</sup> | 105.7 ± 4.6<sup>h</sup> |

| Cell VEGF Protein  |         |     |           |            |
|--------------------|---------|-----|-----------|------------|
| 10μM ALN           | 19.5 ± 1.9<sup>a</sup> | 34.8 ± 1.9<sup>b</sup> | 26.4 ± 1.9<sup>c</sup> | 36.4 ± 1.9<sup>d</sup> |
| 100μM ALN          | 18.6 ± 1.9<sup>e</sup> | 19.4 ± 1.9<sup>f</sup> | 9.7 ± 1.9<sup>g</sup> | 12.4 ± 1.9<sup>h</sup> |

Values expressed as LSMEANS ± SEM. Different superscripts within ALN dose (row) indicate means differ (p < 0.001); n = 6 for each different treatment group within a row.

VEGF188 mRNA used for the bound form. The individual isoforms have distinct roles in angiogenesis and differential regulation of VEGF isoform expression has been reported for many systems [for example, references 28, 29]. A preferential decrease in the secreted VEGF forms by alendronate corresponds to the reduced vascular invasion at the chondro-osseous junction as seen in vivo following treatment with another bisphosphonate, pamidronate [30].

The main mechanism by which nitrogen bisphosphonates alter cellular function is through inhibition of various enzymes of the mevalonate pathway of isoprenoid lipid synthesis [31]. The isoprenoid intermediates farnesyl pyrophosphate and geranylgeranyl pyrophosphate are essential for the post-translational modifications necessary for membrane anchoring and activation of the small GTP associated proteins involved in intracellular signaling. Provision of mevalonate pathway intermediates farnesol (FOH) and geranylgeraniol (GGOH) have been shown to rescue the effects of bisphosphonate mediated inhibition on cellular signaling [8, 32, 33] thereby providing a mechanism to demonstrate whether the alendronate utilized the mevalonate pathway in the inhibition of secreted VEGF in chondrocytes.

Transcript levels of VEGF could be restored at the low alendronate concentration with the addition of GGOH indicating that transcription was regulated by intracellular signaling pathways utilizing geranylgeranylated proteins. The levels of VEGF 120 and 164 were increased only modestly with the addition of FOH. Though alendronate is reported to preferentially alter farnesyl pyrophosphate synthase [35, 36] the present study clearly demonstrates that low alendronate affects geranylgeranylation in cartilage. At the low alendronate dose, reflective of the concentrations experienced by patients receiving bisphosphonates [14], the present data suggest that geranylgeranylation is the preferentially inhibited step in bisphosphonate treatment within growth plate chondrocytes.

The differential response to the mevalonate pathway intermediates is similar to findings of alendronate treated tumor and bone cells [16, 34]. VEGF mRNA expression is known to be regulated by Ras, a farnesylated G protein [37] though recent studies suggest that geranylgeranylated Rho may also be involved in regulating VEGF expression [38]. The data presented here suggest that at low alendronate concentrations, geranylgeranylated proteins such as Rho are involved in the synthesis of the mRNA forms responsible for secreted VEGF. Osteoclasts also rely predominantly upon geranylgeranylated proteins for formation and enzymatic activity [19] suggesting a coordinate regulation of vascular invasion and cartilage resorption at the chondro-osseous junction.

Low alendronate treatment alone and when combined with mevalonate pathway intermediates significantly reduced VEGF protein secreted into the media accompanied by an increase in cell associated VEGF. These data would suggest that alendronate altered the cellular content of both farnesylated and geranylgeranylated proteins important in the secretory process which in turn impaired release of the VEGF protein from the cell. By blocking isoprenoid modification, the alendronate may have further reduced the capacity of the chondrocyte to secrete VEGF beyond a reduction in transcription of the secreted form(s). Blocking secreted VEGF and inhibiting osteoclast function by reducing geranylgeranylated proteins by alendronate is consistent with the impaired vascular invasion and the reduced osteoclastic activity seen with bisphosphonates in vivo [30].

Vascular invasion is a necessary step in bone elongation and reducing that process would be expected to impact bone growth. However, reports of children with osteogenesis imperfecta given bisphosphonate therapy to reduce fractures do not describe negative impacts on bone growth [39]. It is possible that some of the G proteins affected by bisphosphonate treatment promote proliferation while others are involved in signaling pathways driving differentiation within the growth plate [40]. If alendronate at a clinically relevant dose primarily alters geranylgeranylation, it may only impair vascular invasion without negatively affecting prenylation steps involved in chondrocyte proliferation. Thus, the activity of the growth plate might not be significantly reduced, especially in the clinical condition of osteogenesis imperfecta where collagen is impaired. In contrast, normal rodents given bisphosphonates show significantly reduced bone length [7, 30] implying that VEGF inhibition has significant consequences on bone elongation corroborating the data derived from the VEGF knockout mice [5]. This is an important consideration for juvenile patients receiving chronic bisphosphonate treatment.

CONCLUSION

Alendronate, a nitrogen containing bisphosphonate, reduced secreted VEGF at the mRNA, protein, and secretory levels in growth plate chondrocytes indicating that...
Alendronate Inhibits VEGF in the Growth Plate

Bisphosphonates inhibit cellular turnover at the chondro-osseous junction by reducing VEGF induced vascular invasion. This study showed that alendronate acted through the mevalonate pathway, specifically the geranylgeranylation of small GTP associated proteins. Though mRNA isoform levels were restored with the provision of mevalonate pathway intermediates, VEGF protein was only partially restored suggesting additional non-GTP protein associated pathways may be involved in the bisphosphonate inhibition of secreted VEGF protein. Prolonged inhibition of vascular invasion at growth plates reduces bone length. Therefore, the benefits derived from bisphosphonate therapy need to be weighed against the impact on growth plate function in juvenile patients undergoing long-term treatment.

ACKNOWLEDGEMENTS

This work was supported by California Agricultural Experiment Station Funds (CA-D*-ASC-5256-AH). The authors thank Janelle Belanger for technical assistance in the execution of the studies and The Lucy Whittier Molecular & Diagnostic Core Facility at UC Davis for designing and executing the Taqman PCR assays.

REFERENCES

[1] Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Ann J Med 2006; 119(4 Suppl 1): S3-S11.
[2] Madenci E, Yilmaz K, Yilmaz M, Coskun Y. Alendronate treatment in osteoporosis imperfecta. J Clin Rheumatol 2006; 12(2): 53-6.
[3] Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002; 8(5): 1080-4.
[4] Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodelling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5(6): 623-8.
[5] Maes C, Carmeliet P, Moermans K, et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 2002; 111(1-2): 61-73.
[6] Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114(P 5): 853-65.
[7] Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone 2003; 32(3): 268-74.
[8] van Beek ER, Cohen LH, Leroy JM, Ebetino FH, Löwik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003; 33(5): 805-11.
[9] Oberbauer AM, Peng R. Fractionation of growth plate chondrocytes: differential expression of IGF-I and growth hormone and IGF-I receptor mRNA in purified populations. Connect Tissue Res 1995; 31(13): 179-87.
[10] Evans KD, Oberbauer AM. Spatiotemporal localization of VEGF-A isoforms in the mouse postnatal growth plate. Anat Rec (Hoboken) 2008; 291(1): 6-13.
[11] Chua KH, Aminuddin BS, Fuzina NH, Ruszymah BH. Insulin-transferrin-selenium prevent human chondrocyte dedifferentiation and promote the formation of high quality tissue engineered human hyaline cartilage. Eur Cell Mater 2005; 9: 58-67.
[12] Robson H, Siebler T, Shalet SM, Williams GR. Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res 2002; 52(2): 137-47.
[13] Hall AP, Westwood FR, Wadsworth PF. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 2006; 34(2): 131-47.
[14] Spreafico A, Frediani B, Capperucci C, et al. Anabolic effects and inhibition of interleukin 6 production induced by neredronate on human osteoblasts. Reumatismo 2006; 58(4): 288-300.
[15] Farese JP, Ashton J, Milner R, Ambrose LL, Van Gilder J. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim 2004; 40(3-4): 113-7.
[16] Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/geranylgeranyl pyrophosphate synthase activity with relative potencies corresponding to their antiosteotropic potencies in vitro and in vivo. Biochem Biophys Res Commun 1999; 255(2): 491-4.
[17] Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomat Mater 2008; 25(18): 4105-15.
[18] Thomopoulos S, Matsuoka H, Zaege M, Gelberman RH, Silva MJ. Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model. J Orthop Res 2007; 25(4): 473-9.
[19] Russell RG. Bisphosphonates: Mode of action and pharmacology. Pediatrics 2007; 119(Suppl 2): S150-62.
[20] Saag KG. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis 2008; 67(10): 1358-9.
[21] Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 2002; 29(6 Suppl 17): 11-6.
[22] Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13(1): 7-26.
[23] Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005; 25(3): 144-51.
[24] Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302(3): 1055-61.
[25] Zelzer E, Mamluk R, Ferrara N, Olsen BR. VEGF is necessary for chondrocyte survival during bone development. Development 2004; 131(9): 2161-71.
[26] Choi JH, Cho HK, Choi YH, Cheong J. Activating transcription factor 2 increases transactivation and protein stability of hypoxia-inducible factor 1 alpha in hepatocytes. Biochem J 2009; 10.1042/BJ20090371.
[27] Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106(4): 148-56.
[28] Dickinson PJ, Sturges BK, Higgins RJ, et al. Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors. Vet Pathol 2008; 45(2): 131-9.
[29] Birot OJ, Peinnequin A, Simler N, van Cuyck-Gandré H, Hamel R, Bigard XA. Vascular endothelial growth factor expression in heart of rats exposed to hypobaric hypoxia: Differential response between mRNA and protein. J Cell Physiol 2004; 200(1): 107-15.
[30] Evans KD, Sheppard LE, Grossman DI, Martin RB, Oberbauer AM. Long term cyclic pamidronate reduces bone growth by inhibiting osteoblast mediated cartilage-to-bone turnover in the mouse. Open Orthop J 2008; 2: 121-5.
[31] Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ. JBMIR anniversary classic. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, Number 4, pp 581-9 (1998). J Bone Miner Res 2005; 20(7): 1265-74.
[32] Benford HL, Frith JC, Auriola S, Mönkkönen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56(1): 131-40.
[33] Töyräs A, Ollikainen J, Taskinen M, Mönkkönen J. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pharm Sci 2003; 19(4): 223-30.
[34] Andela VB, Pirri M, Schwarz EM, et al. The mevalonate synthesis pathway as a therapeutic target in cancer. Clin Orthop Relat Res 2003; 415(Suppl): S59-66.
[35] Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl pyrophosphate synthase activity with selective inhibition of osteosarcoma cells in vitro. J Bone Miner Res 1999; 14(6): 137-47.
[36] Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl pyrophosphate synthase activity with selective inhibition of osteosarcoma cells in vitro. J Bone Miner Res 1999; 14(6): 137-47.
[37] Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl pyrophosphate synthase activity with selective inhibition of osteosarcoma cells in vitro. J Bone Miner Res 1999; 14(6): 137-47.
[36] Keller RK, Fliesler SJ. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Commun 1999; 266(2): 560-3.

[37] Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: A review. Oncologist 2005; 10(8): 565-78.

[38] Yokota T, Utsunomiya K, Taniguchi K, Gojo A, Kurata H, Tajima N. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol 2007; 51(6): 424-30.

[39] Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111(5 Pt 1): 1030-6.

[40] Wang G, Woods A, Sabari S, Pagnotta L, Stanton LA, Beier F. RhoA/ROCK signaling suppresses hypertrophic chondrocyte differentiation. J Biol Chem 2004; 279(13): 13205-14.

Received: July 30, 2009 Revised: August 31, 2009 Accepted: September 12, 2009

© Evans and Oberbauer; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.